Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data
These findings offer critical evidence for the individualized monitoring and risk management of docetaxel in clinical practice, providing healthcare professionals with the necessary information to optimize treatment regimens and ensure the safe use of docetaxel.
Authors
- Hui Zhao (ORCID: https://orcid.org/0000-0002-3710-3607)
- Peiyun Lv
- Bao Wang (ORCID: https://orcid.org/0009-0007-9330-3412)
- Zhe Wang (ORCID: https://orcid.org/0000-0001-5407-4230)
- Lei Wang (ORCID: https://orcid.org/0000-0002-4342-8520)
- Kunpeng Yang
- Chunhui Cai (ORCID: https://orcid.org/0000-0002-1742-4999)
Institutions
- Jilin Province Tumor Hospital (CN)
- Changchun University of Chinese Medicine (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1371/journal.pone.0331979
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00